For this project on virtual twins we have helped writing the proposal back in early 2023. Max 6 of 65 submitted proposals have been selected for funding. This project made it.
#FraunhoferIZI launches #CERTAINTY with partners, pioneering #VirtualTwin for personalised cancer care. Focused on multiple myeloma, backed by €10M EU, this collaboration is set to transform CAR-T therapy & precision medicine.
👉 https://t.co/qncSqv4Vtu
#InnovativeOncology
November is prostate cancer awareness month.
Prostate cancer is more common than you may think, it is the most frequent cancer among males. This November take some time to learn and spread awareness about this all too common disease.
At our last PIONEER meeting, we showcased the outcomes of our three groundbreaking studyathons. These events brought together diverse experts, conducting data analysis across multiple international datasets.
One paper is already published. More to come!
Now at #ProstatePIONEER_GA23: B. De Meulder and R.Snijder chair the lessons learnt session from #PIONEER's 3️⃣ Studythons🙌
Questions adressed: long-term outcomes of patients on conserv. management, best treatment options and #AEs of systemic treatment in patients with mHSPCa .🩺
Now at #ProstatePIONEER_GA23: B. De Meulder and R.Snijder chair the lessons learnt session from #PIONEER's 3️⃣ Studythons🙌
Questions adressed: long-term outcomes of patients on conserv. management, best treatment options and #AEs of systemic treatment in patients with mHSPCa .🩺
A truly successfull meeting! 🤩 The final #ProstatePIONEER_GA23 has been officially closed by @NDowJames Project Coordinator and @Sevans_axelsson@EFPIA Project Lead 🎗️
We would like to thank everyone who contributed to this successful #GAM 🙏💙
The 3rd #PIONEERStudyAThon23 was a great success! Main achievements: stable analytic platform set up (SAS Viya integrated & tested), study protocol refined, 2 R packages developed, new data sets identified on which study packages can be run, ideas for papers! Congratulations! 👏
Day 2 of #PIONEERStudyAThon_23 successfully came to an end! Results: 5 target cohorts and 21 wrapper #AdverseEvents cohorts were defined in ATLAS! 👏 The study protocol has been refined and will be presented next day. Congratulations! Keep it up! 👏
We are incredibly proud to have consulted and co-written this research proposal for the funding programme HorizonEurope. It was positively evaluated, with a remarkable review of 15 out of 15 points. The project just started, so stay tuned for more news to come!
Webinar invitation:
“Improving clinical research with routine health records – BigData@Heart” with Dipak Kotecha and Folkert Asselbergs.
11 January 2023, 11.30-12.30 CET
register here ->https://t.co/3S5mkzfYn8
Interested in how we have been driving Study-a-Thons as a new paradigm to generate evidence with a dedicated highly focussed group of data partners, domain experts, data scientists, statistician, experts on guidelines?
https://t.co/8vbjj3xCKl
It's amazing the things that get accomplished when you lock a lot of data scientists, researchers, clinicians etc in a room for a week. From the 2 study-a-thons we helped organising we can tell it's fun. More in this recent publication
@OHDSI@IMI_EHDEN
https://t.co/U8pTYXLPLh
Must read: CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research https://t.co/aJhNQez32c
#EHJ#ESCCongress#ESCYoung@ehj_ed@rladeiraslopes
PREFER has issued recommendations on why, when and how to assess and use patient preferences in medical product decision-making.
Need a summary of the take-home messages? #PREFERlegacy 👇
https://t.co/44oJWS1lVg